{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:14:34Z","timestamp":1791940474089,"version":"4.3.4"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Pharma AG"},{"name":"Lundbeck Foundation Professor grant","award":["R310-2018-3711"],"award-info":[{"award-number":["R310-2018-3711"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Erenumab has demonstrated effectiveness for prevention of migraine attacks, but the treatment is costly, and a considerable proportion of patients do not respond to it. The Registry for Migraine study (REFORM) was initiated to discover biomarkers that can predict response to erenumab in patients with migraine. The specific objective was to investigate differences in erenumab efficacy based on clinical information, blood-based biomarkers, structural and functional magnetic resonance imaging (MRI), and response to intravenous infusion of calcitonin gene-related peptide (CGRP). In this first report of the REFORM study, we provide a comprehensive description of the study methodology, and present the baseline characteristics of the study population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The REFORM study was a single-center, prospective, longitudinal cohort study in adults with migraine who were scheduled to receive preventive treatment with erenumab as part of a separate, open-label, single-arm phase IV trial. The study included four periods: a 2-week screening period (Weeks -6 to -5), 4-week baseline period (Week -4 to Day 1), 24-week treatment period (Day 1 to Week 24), and a 24-week follow-up period without treatment (Week 25 to Week 48). Demographic and clinical characteristics were recorded using a semi-structured interview, whilst outcome data were obtained using a headache diary, patient-reported outcomes, blood sampling, brain MRI, and responsiveness to intravenous infusion of CGRP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study enrolled 751 participants, with a mean age\u2009\u00b1\u2009SD of 43.8\u2009\u00b1\u200912.2\u00a0years, of which 88.8% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009667) were female. At enrollment, 64.7% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009486) were diagnosed with chronic migraine, and 30.2% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009227) had history of aura. The mean monthly migraine days (MMDs) was 14.5\u2009\u00b1\u20097.0. Concomitant preventive medications were used by 48.5% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009364) of the participants, and 39.9% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009300) had failed\u2009\u2265\u20094 preventive medications.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The REFORM study enrolled a population with a high migraine burden and frequent use of concomitant medications. The baseline characteristics were representative of patients with migraine in specialized headache clinics. Future publications will report the results of the investigations presented in this article.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The study and sub-studies were registered on ClinicalTrials.gov (NCT04592952; NCT04603976; and NCT04674020).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-023-01604-2","type":"journal-article","created":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T19:02:13Z","timestamp":1686510133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics"],"prefix":"10.1186","volume":"24","author":[{"given":"William Kristian","family":"Karlsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5kan","family":"Ashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Kj\u00e6r","family":"Cullum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune H\u00e4ckert","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidar Muhsen","family":"Al-Khazali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal Mohammad","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Messoud","family":"Ashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the REFORM Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afrim","family":"Iljazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas Vinther","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basit Ali","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betel","family":"Tesfay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janu","family":"Thuraiaiyah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Kokoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja Bredo","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogelio","family":"Dom\u00ednguez-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thien Phu","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan Alice","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"1604_CR1","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s13311-022-01230-x","volume":"19","author":"F Cohen","year":"2022","unstructured":"Cohen F, Yuan H, DePoy EMG, Silberstein SD (2022) The arrival of anti-CGRP monoclonal antibodies in migraine. Neurotherapeutics 19:922\u2013930","journal-title":"Neurotherapeutics"},{"key":"1604_CR2","doi-asserted-by":"publisher","first-page":"175628642092711","DOI":"10.1177\/1756286420927119","volume":"13","author":"AP Andreou","year":"2020","unstructured":"Andreou AP, Fuccaro M, Lambru G (2020) The role of erenumab in the treatment of migraine. Ther Adv Neurol Disord 13:1756286420927119. https:\/\/doi.org\/10.1177\/1756286420927119","journal-title":"Ther Adv Neurol Disord"},{"key":"1604_CR3","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M (2020) Migraine. N Engl J Med 383:1866\u20131876. https:\/\/doi.org\/10.1056\/NEJMra1915327","journal-title":"N Engl J Med"},{"key":"1604_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/S10194-022-01408-W","volume":"23","author":"R Ornello","year":"2022","unstructured":"Ornello R, Baraldi C, Guerzoni S et al (2022) Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study. J Headache Pain 23:38. https:\/\/doi.org\/10.1186\/S10194-022-01408-W","journal-title":"J Headache Pain"},{"key":"1604_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-022-01433-9","volume":"23","author":"C Kjaer Cullum","year":"2022","unstructured":"Kjaer Cullum C, Phu Do T, Ashina M et al (2022) Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study. J Headache Pain 23:61. https:\/\/doi.org\/10.1186\/s10194-022-01433-9","journal-title":"J Headache Pain"},{"key":"1604_CR6","doi-asserted-by":"publisher","first-page":"333102422114631","DOI":"10.1177\/03331024221146315","volume":"43","author":"MJ Lee","year":"2023","unstructured":"Lee MJ, Al-Karagholi MAM, Reuter U (2023) New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy. Cephalalgia 43:3331024221146315","journal-title":"Cephalalgia"},{"key":"1604_CR7","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)32162-0","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Terwindt GM, Al-Karagholi MAM et al (2021) Migraine: disease characterisation, biomarkers, and precision medicine. Lancet (London, England) 397:1496\u20131504. https:\/\/doi.org\/10.1016\/S0140-6736(20)32162-0","journal-title":"Lancet (London, England)"},{"key":"1604_CR8","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/head.12174","volume":"53","author":"P Durham","year":"2013","unstructured":"Durham P, Papapetropoulos S (2013) Biomarkers associated with migraine and their potential role in migraine management. Headache 53:1262\u20131277. https:\/\/doi.org\/10.1111\/head.12174","journal-title":"Headache"},{"key":"1604_CR9","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/ana.26472","volume":"92","author":"A Alpuente","year":"2022","unstructured":"Alpuente A, Gallardo VJ, Asskour L et al (2022) Salivary CGRP and erenumab treatment response: towards precision medicine in migraine. Ann Neurol 92:846\u2013859. https:\/\/doi.org\/10.1002\/ana.26472","journal-title":"Ann Neurol"},{"key":"1604_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-022-01483-z","volume":"23","author":"LS de Vries","year":"2022","unstructured":"de Vries LS, Garrelds IM, Danser AHJ et al (2022) Serum CGRP in migraine patients using erenumab as preventive treatment. J Headache Pain 23:120. https:\/\/doi.org\/10.1186\/s10194-022-01483-z","journal-title":"J Headache Pain"},{"key":"1604_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26658","author":"G G\u00e1rate","year":"2023","unstructured":"G\u00e1rate G, Gonz\u00e1lez-Quintanilla V, Gonz\u00e1lez A et al (2023) Serum alpha and beta-CGRP levels in chronic migraine patients before and after monoclonal antibodies against CGRP or its receptor. Ann Neurol. https:\/\/doi.org\/10.1002\/ana.26658","journal-title":"Ann Neurol"},{"key":"1604_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s10194-022-01526-5","volume":"23","author":"TJ Schwedt","year":"2022","unstructured":"Schwedt TJ, Nikolova S, Dumkrieger G et al (2022) Longitudinal changes in functional connectivity and pain-induced brain activations in patients with migraine: a functional MRI study pre- and post- treatment with Erenumab. J Headache Pain 23:159. https:\/\/doi.org\/10.1186\/s10194-022-01526-5","journal-title":"J Headache Pain"},{"key":"1604_CR13","doi-asserted-by":"publisher","first-page":"333102422114478","DOI":"10.1177\/03331024221144783","volume":"43","author":"S Nikolova","year":"2023","unstructured":"Nikolova S, Chong CD, Dumkrieger GM et al (2023) Longitudinal differences in iron deposition in periaqueductal gray matter and anterior cingulate cortex are associated with response to erenumab in migraine. Cephalalgia 43:3331024221144783. https:\/\/doi.org\/10.1177\/03331024221144783","journal-title":"Cephalalgia"},{"key":"1604_CR14","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association (2013) Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 310:2191\u20132194","journal-title":"JAMA"},{"key":"1604_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M et al (2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61:344\u2013349. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008","journal-title":"J Clin Epidemiol"},{"key":"1604_CR16","first-page":"1","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders. Cephalalgia 38:1\u2013211 (3rd edition)","journal-title":"Cephalalgia"},{"key":"1604_CR17","unstructured":"The National Cancer Institute (NCI) (2010) CTCAE version 4.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm. Accessed 1 Aug 2022"},{"key":"1604_CR18","unstructured":"R Core Team (2021) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. https:\/\/www.R-project.org\/"},{"key":"1604_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","volume":"21","author":"S Sacco","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A et al (2020) European headache federation consensus on the definition of resistant and refractory migraine. J Headache Pain 21:76. https:\/\/doi.org\/10.1186\/s10194-020-01130-5","journal-title":"J Headache Pain"},{"key":"1604_CR20","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"LJ Stovner","year":"2018","unstructured":"Stovner LJ, Nichols E, Steiner TJ et al (2018) Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global burden of disease study 2016. Lancet Neurol 17:954\u2013976. https:\/\/doi.org\/10.1016\/S1474-4422(18)30322-3","journal-title":"Lancet Neurol"},{"key":"1604_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s10194-021-01258-y","volume":"22","author":"A Gago-Veiga","year":"2021","unstructured":"Gago-Veiga A, Huhn JI, Latysheva N et al (2021) InterMiG: international differences in the therapeutic approach to migraine patients in specialized headache centers. J Headache Pain 22:43. https:\/\/doi.org\/10.1186\/s10194-021-01258-y","journal-title":"J Headache Pain"},{"key":"1604_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s10194-021-01250-6","volume":"22","author":"BK Kim","year":"2021","unstructured":"Kim BK, Chu MK, Yu SJ et al (2021) Burden of migraine and unmet needs from the patients\u2019 perspective: a survey across 11 specialized headache clinics in Korea. J Headache Pain 22:45. https:\/\/doi.org\/10.1186\/s10194-021-01250-6","journal-title":"J Headache Pain"},{"key":"1604_CR23","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/head.14375","volume":"62","author":"P Monterrey","year":"2022","unstructured":"Monterrey P, Gonz\u00e1lez M, Ram\u00edrez D et al (2022) Characteristics of migraine in patients with headache disorders: a clinic-based study from Central American and Caribbean countries. Headache 62:1029\u20131038. https:\/\/doi.org\/10.1111\/head.14375","journal-title":"Headache"},{"key":"1604_CR24","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","volume":"81","author":"DC Buse","year":"2010","unstructured":"Buse DC, Manack A, Serrano D et al (2010) Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 81:428\u2013432. https:\/\/doi.org\/10.1136\/jnnp.2009.192492","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1604_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s10194-019-0988-x","volume":"20","author":"T Dresler","year":"2019","unstructured":"Dresler T, Caratozzolo S, Guldolf K et al (2019) Understanding the nature of psychiatric comorbidity in migraine: A systematic review focused on interactions and treatment implications. J Headache Pain 20:51. https:\/\/doi.org\/10.1186\/s10194-019-0988-x","journal-title":"J Headache Pain"},{"key":"1604_CR26","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/da.20600","volume":"26","author":"GJG Asmundson","year":"2009","unstructured":"Asmundson GJG, Katz J (2009) Understanding the co-occurrence of anxiety disorders and chronic pain: State-of-the-art. Depress Anxiety 26:888\u2013901","journal-title":"Depress Anxiety"},{"key":"1604_CR27","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1001\/archinte.163.20.2433","volume":"163","author":"MJ Bair","year":"2003","unstructured":"Bair MJ, Robinson RL, Katon W (2003) Kroenke K Depression and pain comorbidity a literature review. Arch Intern Med 163:2433","journal-title":"Arch Intern Med"},{"key":"1604_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/0333102410373159","volume":"31","author":"H Le","year":"2011","unstructured":"Le H, Tfelt-Hansen P, Russell MB et al (2011) Co-morbidity of migraine with somatic disease in a large population-based study. Cephalalgia 31:43\u201364. https:\/\/doi.org\/10.1177\/0333102410373159","journal-title":"Cephalalgia"},{"key":"1604_CR29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1468-2982.2007.01486.x","volume":"28","author":"AH Aamodt","year":"2008","unstructured":"Aamodt AH, Stovner LJ, Hagen K, Zwart JA (2008) Comorbidity of headache and gastrointestinal complaints the head-HUNT study. Cephalalgia 28:144\u2013151. https:\/\/doi.org\/10.1111\/j.1468-2982.2007.01486.x","journal-title":"Cephalalgia"},{"key":"1604_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s10194-023-01575-4","volume":"24","author":"M Waliszewska-Pros\u00f3\u0142","year":"2023","unstructured":"Waliszewska-Pros\u00f3\u0142 M, Straburzy\u0144ski M, Czapi\u0144ska-Ciepiela EK et al (2023) Migraine symptoms, healthcare resources utilization and disease burden in a large Polish migraine cohort\u202f: Results from \u2019Migraine in Poland\u2019-a nationwide cross-sectional survey. J Headache Pain 24:40. https:\/\/doi.org\/10.1186\/s10194-023-01575-4","journal-title":"J Headache Pain"},{"issue":"8","key":"1604_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41572-021-00328-4","volume":"81","author":"MD Ferrari","year":"2022","unstructured":"Ferrari MD, Goadsby PJ, Burstein R et al (2022) (2022) Migraine. Nat Rev Dis Prim 81(8):1\u201320. https:\/\/doi.org\/10.1038\/S41572-021-00328-4","journal-title":"Nat Rev Dis Prim"},{"key":"1604_CR32","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/ene.15197","volume":"29","author":"F Vernieri","year":"2022","unstructured":"Vernieri F, Altamura C, Brunelli N et al (2022) Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study. Eur J Neurol 29:1198\u20131208. https:\/\/doi.org\/10.1111\/ene.15197","journal-title":"Eur J Neurol"},{"key":"1604_CR33","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/head.14194","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Cevoli S et al (2021) Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. Headache 61:1351\u20131363. https:\/\/doi.org\/10.1111\/head.14194","journal-title":"Headache"},{"key":"1604_CR34","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/ene.15236","volume":"29","author":"C Zecca","year":"2022","unstructured":"Zecca C, Cargnin S, Schankin C et al (2022) Clinic and genetic predictors in response to erenumab. Eur J Neurol 29:1209\u20131217. https:\/\/doi.org\/10.1111\/ene.15236","journal-title":"Eur J Neurol"},{"key":"1604_CR35","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1093\/ije\/dyu115","volume":"43","author":"A Hr\u00f3bjartsson","year":"2014","unstructured":"Hr\u00f3bjartsson A, Emanuelsson F, Thomsen ASS et al (2014) Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies. Int J Epidemiol 43:1272\u20131283. https:\/\/doi.org\/10.1093\/ije\/dyu115","journal-title":"Int J Epidemiol"},{"key":"1604_CR36","doi-asserted-by":"publisher","unstructured":"Nowaczewska M, Straburzy\u0144ski M, Waliszewska-Pros\u00f3\u0142 M, et al (2022) cerebral blood flow and other predictors of responsiveness to erenumab and fremanezumab in migraine\u2014a real-life study. Front Neurol 13;895476. https:\/\/doi.org\/10.3389\/fneur.2022.895476","DOI":"10.3389\/fneur.2022.895476"},{"key":"1604_CR37","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/HEAD.14032","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Egeo G et al (2021) Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache 61:363\u2013372. https:\/\/doi.org\/10.1111\/HEAD.14032","journal-title":"Headache"},{"key":"1604_CR38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/S10194-022-01498-6\/TABLES\/6","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C et al (2022) Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain 23:138. https:\/\/doi.org\/10.1186\/S10194-022-01498-6\/TABLES\/6","journal-title":"J Headache Pain"},{"key":"1604_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01213-3","volume":"22","author":"I Frattale","year":"2021","unstructured":"Frattale I, Caponnetto V, Casalena A et al (2021) Association between response to triptans and response to erenumab: real-life data. J Headache Pain 22:1. https:\/\/doi.org\/10.1186\/s10194-020-01213-3","journal-title":"J Headache Pain"},{"issue":"11","key":"1604_CR40","doi-asserted-by":"publisher","first-page":"e2260","DOI":"10.1002\/brb3.2260","volume":"2021","author":"C Baraldi","year":"2021","unstructured":"Baraldi C, Lo Castro F, Cainazzo MM et al (2021) Predictors of response to erenumab after 12 months of treatment. Brain Behav 2021(11):e2260. https:\/\/doi.org\/10.1002\/brb3.2260","journal-title":"Brain Behav"},{"key":"1604_CR41","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s10072-021-05426-5","volume":"43","author":"U Pensato","year":"2022","unstructured":"Pensato U, Baraldi C, Favoni V et al (2022) Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. Neurol Sci 43:1273\u20131280. https:\/\/doi.org\/10.1007\/s10072-021-05426-5","journal-title":"Neurol Sci"},{"key":"1604_CR42","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-023-01556-7","volume":"24","author":"K Ihara","year":"2023","unstructured":"Ihara K, Ohtani S, Watanabe N et al (2023) Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study. J Headache Pain 24:23. https:\/\/doi.org\/10.1186\/s10194-023-01556-7","journal-title":"J Headache Pain"},{"key":"1604_CR43","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s10194-021-01333-4","volume":"22","author":"S Bottiroli","year":"2021","unstructured":"Bottiroli S, De Icco R, Vaghi G et al (2021) Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study. J Headache Pain 22:114. https:\/\/doi.org\/10.1186\/s10194-021-01333-4","journal-title":"J Headache Pain"},{"key":"1604_CR44","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/ane.13472","volume":"144","author":"M Silvestro","year":"2021","unstructured":"Silvestro M, Tessitore A, Scotto di Clemente F et al (2021) Refractory migraine profile in CGRP-monoclonal antibodies scenario. Acta Neurol Scand 144:325\u2013333. https:\/\/doi.org\/10.1111\/ane.13472","journal-title":"Acta Neurol Scand"},{"key":"1604_CR45","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/ene.15260","volume":"29","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, Fattori D, Benemei S et al (2022) Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. Eur J Neurol 29:1505\u20131513. https:\/\/doi.org\/10.1111\/ene.15260","journal-title":"Eur J Neurol"},{"key":"1604_CR46","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/WCO.0000000000001053","volume":"35","author":"B Tesfay","year":"2022","unstructured":"Tesfay B, Karlsson WK, Moreno RD et al (2022) Is calcitonin gene-related peptide a reliable biochemical marker of migraine? Curr Opin Neurol 35:343\u2013352. https:\/\/doi.org\/10.1097\/WCO.0000000000001053","journal-title":"Curr Opin Neurol"},{"key":"1604_CR47","doi-asserted-by":"publisher","first-page":"2118543","DOI":"10.1001\/jamanetworkopen.2021.18543","volume":"4","author":"L Pellesi","year":"2021","unstructured":"Pellesi L, Al-Karagholi MAM, De Icco R et al (2021) Effect of vasoactive intestinal polypeptide on development of migraine headaches: a randomized clinical trial. JAMA Netw Open 4:2118543. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.18543","journal-title":"JAMA Netw Open"},{"key":"1604_CR48","doi-asserted-by":"publisher","first-page":"e2488","DOI":"10.1212\/WNL.0000000000011930","volume":"96","author":"H Ghanizada","year":"2021","unstructured":"Ghanizada H, Al-Karagholi MAM, Arngrim N et al (2021) Effect of adrenomedullin on migraine-like attacks in patients with migraine: a randomized crossover study. Neurology 96:e2488\u2013e2499. https:\/\/doi.org\/10.1212\/WNL.0000000000011930","journal-title":"Neurology"},{"key":"1604_CR49","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1177\/03331024221118924","volume":"42","author":"J Thuraiaiyah","year":"2022","unstructured":"Thuraiaiyah J, Erritz\u00f8e-Jervild M, Al-Khazali HM et al (2022) The role of cytokines in migraine: a systematic review. Cephalalgia 42:1565\u20131588","journal-title":"Cephalalgia"},{"key":"1604_CR50","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1526-4610.2008.01228.x","volume":"49","author":"M Teepker","year":"2009","unstructured":"Teepker M, Munk K, Mylius V et al (2009) Serum concentrations of s100b and NSE in migraine. Headache 49:245\u2013252. https:\/\/doi.org\/10.1111\/j.1526-4610.2008.01228.x","journal-title":"Headache"},{"key":"1604_CR51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s10194-021-01271-1","volume":"22","author":"O Kursun","year":"2021","unstructured":"Kursun O, Yemisci M, van den Maagdenberg AMJM, Karatas H (2021) Migraine and neuroinflammation: the inflammasome perspective. J Headache Pain 22:55","journal-title":"J Headache Pain"},{"key":"1604_CR52","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41582-021-00544-2","volume":"17","author":"DN Krause","year":"2021","unstructured":"Krause DN, Warfvinge K, Haanes KA, Edvinsson L (2021) Hormonal influences in migraine \u2014 interactions of oestrogen, oxytocin and CGRP. Nat Rev Neurol 17:621\u2013633","journal-title":"Nat Rev Neurol"},{"key":"1604_CR53","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/head.14412","volume":"63","author":"MAM Al-Karagholi","year":"2023","unstructured":"Al-Karagholi MAM, Kalatharan V, Ghanizada H et al (2023) Prolactin in headache and migraine: a systematic review of preclinical studies. Headache 63:577","journal-title":"Headache"},{"key":"1604_CR54","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40122-021-00240-5","volume":"10","author":"S Ashina","year":"2021","unstructured":"Ashina S, Bentivegna E, Martelletti P, Eikermann-Haerter K (2021) Structural and functional brain changes in migraine. Pain Ther 10:211\u2013223","journal-title":"Pain Ther"},{"key":"1604_CR55","doi-asserted-by":"publisher","first-page":"333102422112827","DOI":"10.1177\/03331024221128278","volume":"43","author":"S Schramm","year":"2023","unstructured":"Schramm S, B\u00f6rner C, Reichert M et al (2023) Functional magnetic resonance imaging in migraine: a systematic review. Cephalalgia 43:3331024221128278","journal-title":"Cephalalgia"},{"key":"1604_CR56","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/WCO.0000000000001060","volume":"35","author":"R Messina","year":"2022","unstructured":"Messina R, Gollion C, Christensen RH, Amin FM (2022) Functional MRI in migraine. Curr Opin Neurol 35:328\u2013335","journal-title":"Curr Opin Neurol"},{"key":"1604_CR57","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s10194-019-1047-3","volume":"20","author":"K Skorobogatykh","year":"2019","unstructured":"Skorobogatykh K, Van Hoogstraten WS, Degan D et al (2019) Functional connectivity studies in migraine: What have we learned? J Headache Pain 20:108","journal-title":"J Headache Pain"},{"key":"1604_CR58","doi-asserted-by":"publisher","first-page":"E2794","DOI":"10.1212\/WNL.0000000000010740","volume":"95","author":"C Ziegeler","year":"2020","unstructured":"Ziegeler C, Mehnert J, Asmussen K, May A (2020) Central effects of erenumab in migraine patients: An event-related functional imaging study. Neurology 95:E2794\u2013E2802. https:\/\/doi.org\/10.1212\/WNL.0000000000010740","journal-title":"Neurology"},{"key":"1604_CR59","doi-asserted-by":"publisher","first-page":"e77146","DOI":"10.7554\/eLife.77146","volume":"11","author":"H Basedau","year":"2022","unstructured":"Basedau H, Sturm LM, Mehnert J et al (2022) Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target \u2013 an fMRI study. Elife 11:e77146. https:\/\/doi.org\/10.7554\/eLife.77146","journal-title":"Elife"},{"key":"1604_CR60","doi-asserted-by":"publisher","first-page":"7900","DOI":"10.1073\/pnas.1602413113","volume":"113","author":"A Eklund","year":"2016","unstructured":"Eklund A, Nichols TE, Knutsson H (2016) Cluster failure: Why fMRI inferences for spatial extent have inflated false-positive rates. Proc Natl Acad Sci U S A 113:7900\u20137905. https:\/\/doi.org\/10.1073\/pnas.1602413113","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1604_CR61","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s10194-022-01464-2","volume":"23","author":"H Ashina","year":"2022","unstructured":"Ashina H, Christensen RH, Ashina M (2022) Provoked versus spontaneous migraine attacks: pathophysiological similarities and differences. J Headache Pain 23:87","journal-title":"J Headache Pain"},{"key":"1604_CR62","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s10194-018-0927-2","volume":"19","author":"CE Christensen","year":"2018","unstructured":"Christensen CE, Younis S, Deen M et al (2018) Migraine induction with calcitonin gene-related peptide in patients from erenumab trials. J Headache Pain 19:105. https:\/\/doi.org\/10.1186\/s10194-018-0927-2","journal-title":"J Headache Pain"},{"key":"1604_CR63","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/03331024211046617","volume":"42","author":"B Raffaelli","year":"2022","unstructured":"Raffaelli B, Terhart M, Overeem LH et al (2022) Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia 42:326\u2013334. https:\/\/doi.org\/10.1177\/03331024211046617","journal-title":"Cephalalgia"},{"key":"1604_CR64","doi-asserted-by":"publisher","unstructured":"De Matteis E, Affaitati G, Frattale I, et al Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. https:\/\/doi.org\/10.1007\/s10072-020-05022-z\/Published","DOI":"10.1007\/s10072-020-05022-z\/Published"},{"key":"1604_CR65","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/03331024211014616","volume":"41","author":"AR Gantenbein","year":"2021","unstructured":"Gantenbein AR, Agosti R, Gobbi C et al (2021) Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment \u2013 a real-life cohort study. Cephalalgia 41:1181\u20131186. https:\/\/doi.org\/10.1177\/03331024211014616","journal-title":"Cephalalgia"},{"key":"1604_CR66","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/head.13508","volume":"59","author":"VL Stauffer","year":"2019","unstructured":"Stauffer VL, Wang S, Voulgaropoulos M et al (2019) Effect of galcanezumab following treatment cessation in patients with migraine: results from 2 randomized phase 3 trials. Headache 59:834\u2013847. https:\/\/doi.org\/10.1111\/head.13508","journal-title":"Headache"},{"key":"1604_CR67","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s10194-019-1018-8","volume":"20","author":"B Raffaelli","year":"2019","unstructured":"Raffaelli B, Mussetto V, Israel H et al (2019) Erenumab and galcanezumab in chronic migraine prevention: Effects after treatment termination. J Headache Pain 20:66. https:\/\/doi.org\/10.1186\/s10194-019-1018-8","journal-title":"J Headache Pain"},{"key":"1604_CR68","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1111\/head.13184","volume":"57","author":"S Bandarian-Balooch","year":"2017","unstructured":"Bandarian-Balooch S, Martin PR, McNally B et al (2017) Electronic-diary for recording headaches, triggers, and medication use: development and evaluation. Headache 57:1551\u20131569. https:\/\/doi.org\/10.1111\/head.13184","journal-title":"Headache"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01604-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01604-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01604-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T19:02:21Z","timestamp":1686510141000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01604-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1604"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01604-2","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]},"assertion":[{"value":"25 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The REFORM study received approval from both the Danish Data Protection Agency and the ethics committee of the Capital Region of Denmark (H-20033264 and H-20047793). All participants were given appropriate time to consider participation and provided written informed consent before undergoing any study-related procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"WKK, CKC, HMA, and RHC declare no competing interests. HA reports receiving personal fees from Teva outside of the submitted work. FMA reports receiving personal fees from AbbVie, Pfizer, Teva, Lundbeck, Novartis, and Eli Lilly outside of the submitted work. FMA serves as an associate editor of Frontiers in Neurology, Frontiers in Pain Research, Headache Medicine and Acta Neurologica Scandinavica, and as junior associate editor of Cephalalgia. MA reports receiving personal fees from AbbVie, Amgen, Eli Lilly, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals outside of the submitted work. MA also serves as an associate editor of Cephalalgia, The Journal of Headache and Pain, and Brain.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}